Industry Session

Industry Roundtable: Critical considerations, challenges, opportunities and strategies in development of once a day (QD) formulations

Speaker(s)

• FA

  Firouz Asgarzadeh

  Lead Product Development Consultant
  Sagimet
• 

  Sandip Tiwari, PhD (he/him/his)

  Head of Technical Services-Pharma Solutions NA
  BASF, New York, United States
• AK

  Anil Kane

  Head of Global Technical Scientific Affairs
  Thermo Fisher Scientific
• MD

  Matt Dawes

  Vice President, Commercial Operations, DPD OSD & Soft Gels
  Thermo Fisher Scientific

Once a day (QD) drug product development has gained importance due to reduced frequency of dosing and patient compliance. However, many new chemical entities in the clinical pipeline may not have the optimal properties for development of a QD formulations. Challenges of poor solubility, permeability, stability and the drug dose could be some of the critical factors that impact the product development. Selection of the optimum principle, mechanism and technology available to release the rate and extent of the drug at the target site of absorption and efficacy is key to a speedy development and proof of efficacy in human subjects is extremely important. Several critical factors and considerations related to the challenges will be discussed by the panel of experts.